Express Pharma
Home  »  Latest Updates  »  US FDA completes inspection of Strides Pharma Bengaluru plant

US FDA completes inspection of Strides Pharma Bengaluru plant

The company's facility in Bengaluru underwent a United States Food and Drug Administration (US FDA) inspection that ended on May 24, 2019, Strides Pharma Science said in a statement

0 122
Read Article

Drug firm Strides Pharma Science said the inspection of its formulation facility in Bengaluru by the US health regulator has completed successfully with a voluntary action indicated (VAI) classification. The company’s facility in Bengaluru underwent a United States Food and Drug Administration (US FDA) inspection that ended on May 24, 2019, Strides Pharma Science said in a statement.

The Bengaluru facility is the largest manufacturing facility for the company with capabilities to produce finished dosage formulation products across multiple dosage formats including tablet, capsules, ointments, creams and liquids, Strides Pharma said.

The facility services key regulated markets of the US, Europe, and Australia, it added.

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Attend India's Largest Pharma Packaging & Labelling Conclave
Register Now
close-image
Create a Clear Path To Global Success
Register Now
close-image